Imaging B Cells in a Mouse Model of Multiple Sclerosis Using 64Cu-Rituximab PET
Open Access
- 7 July 2017
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (11) , 1845-1851
Abstract
B lymphocytes are a key pathologic feature of multiple sclerosis (MS) and are becoming an important therapeutic target for this condition. Currently, there is no approved technique to noninvasively visualize B cells in the central nervous system (CNS) to monitor MS disease progression and response to therapies. Here, we evaluated 64Cu-rituximab, a radiolabeled antibody specifically targeting the human B cell marker CD20, for its ability to image B cells in a mouse model of MS using PET. Methods: To model CNS infiltration by B cells, experimental autoimmune encephalomyelitis (EAE) was induced in transgenic mice that express human CD20 on B cells. EAE mice were given subcutaneous injections of myelin oligodendrocyte glycoprotein fragment1–125 emulsified in complete Freund adjuvant. Control mice received complete Freund adjuvant alone. PET imaging of EAE and control mice was performed 1, 4, and 19 h after 64Cu-rituximab administration. Mice were perfused and sacrificed after the final PET scan, and radioactivity in dissected tissues was measured with a γ-counter. CNS tissues from these mice were immunostained to quantify B cells or were further analyzed via digital autoradiography. Results: Lumbar spinal cord PET signal was significantly higher in EAE mice than in controls at all evaluated time points (e.g., 1 h after injection: 5.44 ± 0.37 vs. 3.33 ± 0.20 percentage injected dose [%ID]/g, P < 0.05). 64Cu-rituximab PET signal in brain regions ranged between 1.74 ± 0.11 and 2.93 ± 0.15 %ID/g for EAE mice, compared with 1.25 ± 0.08 and 2.24 ± 0.11 %ID/g for controls (P < 0.05 for all regions except striatum and thalamus at 1 h after injection). Similarly, ex vivo biodistribution results revealed notably higher 64Cu-rituximab uptake in the brain and spinal cord of huCD20tg EAE, and B220 immunostaining verified that increased 64Cu-rituximab uptake in CNS tissues corresponded with elevated B cells. Conclusion: B cells can be detected in the CNS of EAE mice using 64Cu-rituximab PET. Results from these studies warrant further investigation of 64Cu-rituximab in EAE models and consideration of use in MS patients to evaluate its potential for detecting and monitoring B cells in the progression and treatment of this disease. These results represent an initial step toward generating a platform to evaluate B cell–targeted therapeutics en route to the clinic.Keywords
This publication has 17 references indexed in Scilit:
- Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 EpitopeRadiology, 2015
- Role of the Blood–Brain Barrier in Multiple SclerosisArchives of Medical Research, 2014
- B cell follicle-like structures in multiple sclerosis—With focus on the role of B cell activating factorJournal of Neuroimmunology, 2014
- Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic ReviewPLOS ONE, 2013
- B cells and antibodies in multiple sclerosis pathogenesis and therapyNature Reviews Neurology, 2012
- New Positron Emission Tomography (PET) Radioligand for Imaging σ-1 Receptors in Living SubjectsJournal of Medicinal Chemistry, 2012
- Positron Emission Tomography of 64Cu-DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHLMolecular Imaging and Biology, 2012
- Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune EncephalomyelitisPLOS ONE, 2011
- The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody ImmunotherapyJournal of Experimental Medicine, 2004
- Determination of the Immunoreactivity of Radiolabeled Monoclonal Antibodies2000